{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100.0","upperLimit":"100.0","value":"100"},{"groupId":"OG001","lowerLimit":"100.0","upperLimit":"100.0","value":"100"},{"groupId":"OG002","lowerLimit":"100.0","upperLimit":"100.0","value":"100"},{"groupId":"OG003","lowerLimit":"100.0","upperLimit":"100.0","value":"100"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"The percentage of participants with a clinicopathologic response will be reported for all participants along with a 95% confidence interval. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \\<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on available studies. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ended treatment at the regular dose level: 80 intravenous (IV)/80 Intraperitoneal (IP) + 300 twice a day (BID).","id":"OG000","title":"Intravenous Paclitaxel Dose Level 1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1"},{"description":"Had the planned doses for Intraperitoneal (IP) Paclitaxel (80 IP) and by mouth (PO) nilotinib (300 twice a day (BID) but declined to go up to the 80mg/m\\^2 of intravenous (IV) Paclitaxel.","id":"OG001","title":"Intravenous Paclitaxel DoseLevel -1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1"},{"description":"Had the planned doses for intravenous (IV) and Intraperitoneal (IP) Paclitaxel (80 IV/80 IP) but had a dose reduction for Nilotinib (400 every day (QD).","id":"OG002","title":"Intravenous Paclitaxel DoseLevel 1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level -1"},{"description":"Had the planned dose of Intraperitoneal (IP) Paclitaxel (80 IP) but had a dose reduction for intravenous (IV) Paclitaxel (60 IV), and a dose reduction for Nilotinib (400 every day (QD).","id":"OG003","title":"Intravenous Paclitaxel DoseLevel -1, Intraperitoneal Paclitaxel DoseLevel 1, Nilotinib Dose Level -1"}],"paramType":"NUMBER","populationDescription":"7/21 participants were analyzed because 12 participants were not treated and 2 refused further treatment, for the duration of the study (27 months, 14 days).","reportingStatus":"POSTED","timeFrame":"Participants were followed from baseline, every 9 weeks during treatment, and then every 3 months through study completion for 27 months, 14 days","title":"Percentage of Participants With a Clinicopathologic Response to Therapy by Response Evaluation Criteria in Solid Tumor (RECIST)v 1.1 Reported With a 95% Confidence Interval","type":"SECONDARY","unitOfMeasure":"percentage of participants"}